BIONTECH Stock Price, News & Analysis

BioNTech (NASDAQ: BNTX) has scheduled its second quarter 2025 financial results announcement and corporate update for August 4, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day.

Investors and analysts can access the conference call via telephone by registering through a provided link, which will supply dial-in numbers and a PIN. The presentation slides and webcast will be accessible through the company's website, with a replay available for 30 days after the event.

BioNTech (NASDAQ: BNTX) announced that Chief Strategy Officer Ryan Richardson will step down from the Management Board effective September 30, 2025. Richardson, who joined in 2018 and served as CSO since January 2020, played a crucial role in the company's development, including raising over $1 billion in capital through Series B financing, IPO, and follow-on offerings.

During his tenure, Richardson led Global Strategy and Corporate Development functions, overseeing more than a dozen collaborations and acquisitions. He also managed Capital Markets and Investor Relations, expanding analyst coverage and strengthening BioNTech's global shareholder base. His responsibilities will be transitioned to other Management Board members to ensure a smooth handover.

BioNTech SE (Nasdaq: BNTX) reported Q1 2025 financial results with revenues of €182.8 million, primarily driven by COVID-19 vaccine collaboration. The company posted a net loss of €415.8 million and loss per share of €1.73. Despite losses, BioNTech maintains a strong financial position with €15.9 billion in cash and investments.

Key highlights include advancement in oncology pipeline, particularly BNT327 (PD-L1xVEGF-A bispecific antibody) and mRNA cancer immunotherapies. The company confirmed its 2025 revenue guidance of €1.7-2.2 billion and announced preparation for 2025/2026 variant-adapted COVID-19 vaccine.

BioNTech (BNTX) announced a strategic all-stock acquisition of CureVac in a deal valued at approximately $1.25 billion. Under the agreement, each CureVac share will be exchanged for $5.46 in BioNTech ADSs, representing a 55% premium to CureVac's three-month volume weighted average price. The acquisition aims to strengthen BioNTech's oncology strategy by combining both companies' mRNA capabilities in research, development, manufacturing, and commercialization of cancer immunotherapy candidates. The transaction, expected to close in 2025, has received unanimous approval from both companies' boards and support from CureVac's major shareholders, representing 50.08% of shares. Upon closing, CureVac shareholders will own between 4-6% of BioNTech, and CureVac's operating subsidiary will become wholly owned by BioNTech, including its Tübingen research and manufacturing site.

BioNTech and Bristol Myers Squibb have announced a major global strategic partnership to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A for multiple solid tumor types. BMS will pay BioNTech $1.5B upfront, $2B in non-contingent payments through 2028, and up to $7.6B in additional milestones. The companies will share development costs and profits/losses 50:50. BNT327 is currently in multiple trials with over 1,000 patients, including Phase 3 trials for small cell lung cancer and non-small cell lung cancer, with a planned Phase 3 trial for triple negative breast cancer starting by end of 2025. The collaboration aims to accelerate BNT327's development and potential regulatory approvals, leveraging both companies' expertise in immuno-oncology.

BioNTech (NASDAQ: BNTX) will present clinical trial data from its oncology pipeline at the 2025 ASCO Annual Meeting in Chicago. Key highlights include: BNT327 (anti-PD-L1xVEGF-A antibody): - Phase 2 data showing anti-tumor activity in mesothelioma - Ongoing Phase 3 trials in small cell lung cancer and non-small cell lung cancer BNT324/DB-1311 (B7H3-targeted ADC): - Phase 1/2 data in prostate cancer showing early clinical activity - Received FDA Fast Track Designation in 2024 BNT316/ONC-392 (gotistobart): - Phase 1/2 trials showing manageable safety in melanoma and prostate cancer - Preliminary efficacy data in advanced melanoma BNT142 (mRNA immunotherapy): - Phase 1/2 data in CLDN6-positive tumors - Early signs of clinical activity with manageable safety BioNTech has over 20 active Phase 2 and 3 trials, with multiple data readouts expected in 2025-2026.

BioNTech (BNTX) reported Q1 2025 financial results with revenues of €182.8M, down slightly from €187.6M in Q1 2024. The company posted a net loss of €415.8M (€1.73 per share), compared to a €315.1M loss in Q1 2024. Despite losses, BioNTech maintains a strong financial position with €15.9B in cash and investments. The company's oncology pipeline shows progress, particularly with BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, showing promising clinical results. BioNTech confirmed its 2025 revenue guidance of €1.7B-€2.2B, with R&D expenses projected at €2.6B-€2.8B. The company is preparing for a 2025/2026 season variant-adapted COVID-19 vaccine launch and announced Ramón Zapata-Gomez as new CFO effective July 2025.

BioNTech (NASDAQ: BNTX) has appointed Ramón Zapata-Gomez as its new Chief Financial Officer, effective July 1, 2025. Zapata will succeed Jens Holstein, who will retire as planned on June 30, 2025. Zapata joins from Novartis AG, where he served as CFO of their global biomedical research organization since 2022.

With over 25 years of experience in pharmaceutical and consumer goods industries, Zapata brings extensive expertise in finance, M&A, and digital transformations. His appointment aligns with BioNTech's strategy to become a multi-product oncology company. In his new role, Zapata will focus on optimizing financial infrastructure, performance in key markets, and driving cost-effective value generation as the company prepares for oncology product launches.

BioNTech (NASDAQ: BNTX) will showcase data from its oncology pipeline at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentations will feature:

1. BNT327: A next-generation bispecific antibody showing superior anti-tumor activity in preclinical studies when combined with antibody-drug conjugates (ADCs)

2. BNT116: Phase 1 clinical trial data in combination with cemiplimab for non-small cell lung cancer (NSCLC), demonstrating anti-tumor activity and manageable safety profile

3. BNT314/GEN1059: Preclinical data showing enhanced anti-tumor activity when combined with PD-1 inhibition

The company's oncology portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, with over 20 active Phase 2 and 3 trials. Multiple data readouts are expected in 2025 and 2026.